Keith Humphreys, P Todd Korthuis, Daniel Stjepanović, Wayne Hall
{"title":"迷幻药的治疗潜力:驾驭殷切希望、强烈宣称、薄弱证据和巨额资金。","authors":"Keith Humphreys, P Todd Korthuis, Daniel Stjepanović, Wayne Hall","doi":"10.1146/annurev-psych-020124-023532","DOIUrl":null,"url":null,"abstract":"<p><p>Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is strengthening however, making it easier to differentiate some promising findings amid the hype that suffuses this research area. Ketamine has risks of adverse side effects (e.g., addiction and cystitis), but multiple studies suggest it can benefit individuals with treatment-resistant depression. Other therapeutic signals from psychedelic drug research that merit rigorous replication studies include 3,4-Methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD) and psilocybin for depression, end of life dysphoria, and alcohol use disorder. The precise mechanisms through which psychedelic drugs can produce benefit and harm are not fully understood. Rigorous research is the best path forward for evaluating the therapeutic potential and mechanisms of psychedelic drugs. Policies governing the clinical use of these drugs should be informed by evidence and prioritize the protection of public health over the profit motive.</p>","PeriodicalId":8010,"journal":{"name":"Annual review of psychology","volume":" ","pages":""},"PeriodicalIF":23.6000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money.\",\"authors\":\"Keith Humphreys, P Todd Korthuis, Daniel Stjepanović, Wayne Hall\",\"doi\":\"10.1146/annurev-psych-020124-023532\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is strengthening however, making it easier to differentiate some promising findings amid the hype that suffuses this research area. Ketamine has risks of adverse side effects (e.g., addiction and cystitis), but multiple studies suggest it can benefit individuals with treatment-resistant depression. Other therapeutic signals from psychedelic drug research that merit rigorous replication studies include 3,4-Methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD) and psilocybin for depression, end of life dysphoria, and alcohol use disorder. The precise mechanisms through which psychedelic drugs can produce benefit and harm are not fully understood. Rigorous research is the best path forward for evaluating the therapeutic potential and mechanisms of psychedelic drugs. Policies governing the clinical use of these drugs should be informed by evidence and prioritize the protection of public health over the profit motive.</p>\",\"PeriodicalId\":8010,\"journal\":{\"name\":\"Annual review of psychology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":23.6000,\"publicationDate\":\"2024-08-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annual review of psychology\",\"FirstCategoryId\":\"102\",\"ListUrlMain\":\"https://doi.org/10.1146/annurev-psych-020124-023532\",\"RegionNum\":1,\"RegionCategory\":\"心理学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual review of psychology","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1146/annurev-psych-020124-023532","RegionNum":1,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHOLOGY","Score":null,"Total":0}
Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money.
Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is strengthening however, making it easier to differentiate some promising findings amid the hype that suffuses this research area. Ketamine has risks of adverse side effects (e.g., addiction and cystitis), but multiple studies suggest it can benefit individuals with treatment-resistant depression. Other therapeutic signals from psychedelic drug research that merit rigorous replication studies include 3,4-Methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD) and psilocybin for depression, end of life dysphoria, and alcohol use disorder. The precise mechanisms through which psychedelic drugs can produce benefit and harm are not fully understood. Rigorous research is the best path forward for evaluating the therapeutic potential and mechanisms of psychedelic drugs. Policies governing the clinical use of these drugs should be informed by evidence and prioritize the protection of public health over the profit motive.
期刊介绍:
The Annual Review of Psychology, a publication that has been available since 1950, provides comprehensive coverage of the latest advancements in psychological research. It encompasses a wide range of topics, including the biological underpinnings of human behavior, the intricacies of our senses and perception, the functioning of the mind, animal behavior and learning, human development, psychopathology, clinical and counseling psychology, social psychology, personality, environmental psychology, community psychology, and much more. In a recent development, the current volume of this esteemed journal has transitioned from a subscription-based model to an open access format as part of the Annual Reviews' Subscribe to Open initiative. As a result, all articles published in this volume are now freely accessible to the public under a Creative Commons Attribution (CC BY) license.